Initial clinical activity in a PD-(L)1 resistant population, with an ORR almost three times higher than historical PD-(L)1 ...

Radiopharm Theranostics Limited targets oncology with radiotherapeutics like Lu-RAD204 for NSCLC. Key 2025 data signals ...

Predictive biomarkers of immunotherapy response are critical for clinical practice. In this study, baseline plasma sCD27 was ...

BioAtla is extending its runway beyond key clinical readouts in 1H 2026 by restructuring and realigning resources, which ...

Encouraging efficacy data in a murine mesothelioma model with a selective A2B adenosine receptor antagonist given as a single agent or in combination ...

We recently published a list of 10 Hot Biotech Stocks Under $5. In this article, we are going to take a look at where Compass ...

Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel therapies that address emerging targets in oncology, today announced it will present preclinical ...

SUZHOU, China, March 27, 2025 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a biopharmaceutical company dedicated to developing innovative cancer therapies, today reported 2024 annual ...

BeyondSpring , with significant clinical progress for our first-in-class agent Plinabulin and strategic advancements for SEED Therapeutics, which Be ...

Innovent is a leading biotech company in China with strong roots in oncology, anchored by its core PD-1 drug Tyvyt. The price cut for PD-1 drugs has stabilized gradually. Hence, we expect stable ...

Q4 2024 Earnings Conference Call March 27, 2025 4:30 PM ETCompany ParticipantsBruce Mackle - LifeSci Advisors, ...

Japanese drug firm Chugai Pharmaceutical has established competitive advantages due to its alliance with majority shareholder Roche as well as its internal research and development engine. While ...